as 05-17-2024 4:00pm EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Founded: | 2007 | Country: | Germany |
Employees: | N/A | City: | N/A |
Market Cap: | 69.5M | IPO Year: | 2017 |
Target Price: | $13.50 | AVG Volume (30 days): | 219.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.78 | EPS Growth: | N/A |
52 Week Low/High: | $1.14 - $4.70 | Next Earning Date: | 05-08-2024 |
Revenue: | $107,746 | Revenue Growth: | N/A |
Revenue Growth (this year): | 7127.88% | Revenue Growth (next year): | 59.54% |
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
GlobeNewswire
18 days ago
GlobeNewswire
24 days ago
Zacks
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
Simply Wall St.
2 months ago
GlobeNewswire
3 months ago